Clinical Trials Logo

Rectal Diseases clinical trials

View clinical trials related to Rectal Diseases.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05551052 Active, not recruiting - Colorectal Cancer Clinical Trials

CRC Detection Reliable Assessment With Blood

CRC-DRAW
Start date: September 8, 2022
Phase:
Study type: Observational

The CRC DRAW study will assess the sensitivity and specificity of the blood-based, Next-Gen CRC Screening Test for the detection of CRC.

NCT ID: NCT04369053 Active, not recruiting - Colorectal Cancer Clinical Trials

Prevention of Colorectal Cancer Through Multiomics Blood Testing

PREEMPT CRC
Start date: May 20, 2020
Phase:
Study type: Observational

The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy.

NCT ID: NCT02005965 Active, not recruiting - Neoplasms Clinical Trials

Low Rectal Cancer Study (MERCURY II)

MERCURY II
Start date: August 13, 2007
Phase:
Study type: Observational

The MERCURY Study demonstrated the accuracy, feasibility and reproducibility of Magnetic Resonance Imaging (MRI) to stage rectal cancer in a prospective, multidisciplinary, multi-centre study. However, there were differences in patient outcome, dependent upon the position of the tumour in the rectum and its height above the anal verge. Whilst the outcome was excellent for patients who underwent an anterior resection, the outcome, based upon margin involvement and quality of the specimen, was poor for patients who underwent an abdomino-perineal excision for low rectal cancer. It is proposed that accurate MRI staging pre-operatively will allow the correct patients to receive neo-adjuvant chemoradiotherapy (CRT), and also pre-warn the surgeons if the resection margins appear threatened so that the operation can be modified to take this into account. The primary aims of the Low Rectal Cancer Study (MERCURY II) are to assess the rate of CRM positivity rate in low rectal cancer and to assess the difference in global quality of life at two years post surgery in patients according to plane of surgery with or without sphincter preservation.

NCT ID: NCT01995942 Active, not recruiting - Neoplasms Clinical Trials

Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial

MARVEL
Start date: June 7, 2013
Phase:
Study type: Observational

Extramural venous invasion (EMVI) is the spread of microscopic tumour cells into the veins around the tumour. Rectal cancer treatment has improved greatly over recent years. However, it is important for us to learn as much about the tumours as possible in order to develop newer therapies. Current treatments may benefit from new genetic information relating to the cancer. We hope to identify genetic differences in certain types of rectal cancer which will allow future treatments.

NCT ID: NCT01037049 Active, not recruiting - Neoplasms Clinical Trials

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

Start date: October 16, 2009
Phase: Phase 2
Study type: Interventional

The aim of this study is to determine whether greater rectal cancer downstaging and regression occurs when surgery is delayed to 12 weeks after completion of radiotherapy/chemotherapy compared to 6 weeks. Hypothesis: Greater downstaging and tumour regression is observed when surgery is delayed to 12 weeks after completion of CRT compared to 6 weeks.